ISI Group raised its rating on Allscripts Healthcare Solution MDRX from Market-weight to Overweight and increased its price target to $14.50.
ISI Group noted, "Late Friday, Bloomberg released a story that Allscripts is exploring a sale of the company and is in talks with private equity about a potential buyout. According to an unnamed source (“someone familiar with the matter”) MDRX has been in talks with several private equity firms and MDRX has hired advisors for a potential sale. Also according to the source, MDRX still may not sell the business. Based on this release, with a 50% probability for a deal (with an LBO valuation of $16.50) and a standalone base valuation of $12.50 (~13x FY13 P/E), we have upgraded shares to Overweight and increased our PT to $14.50."
Allscripts Healthcare Solutions closed at $12.42 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in